Key Trend Reshaping the Lung Cancer Diagnostic And Screening Market in 2025: Freenome Launches PROACT LUNG Trial For Enhanced Early Detection

What combination of drivers is leading to accelerated growth in the lung cancer diagnostic and screening market?
The lung cancer diagnostic and screening market is likely to experience growth as a result of the rising incidence of lung cancer. Lung cancer, a dangerous ailment marked by unrestricted cell growth in lung tissues, presents symptoms such as chest pain, cough, and breathing difficulties. Early diagnosis of this disease in patients, using various tests like incisional biopsy and bronchoscopy, is facilitated by lung cancer diagnosis and screening. For example, the American Cancer Society, a US-based government entity, reported in January 2023 that the United States had an estimated 238,340 new lung cancer cases (117,550 in men and 120,790 in women). In addition, it was reported that there were approximately 127,070 lung cancer deaths (67,160 in men and 59,910 in women). Therefore, the escalating prevalence of lung cancer is fueling the expansion of the lung cancer diagnostic and screening market.

Get Your Lung Cancer Diagnostic And Screening Market Report Here:
https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

What is the projected compound annual growth rate (CAGR) of the lung cancer diagnostic and screening market from 2025 to 2034, and what factors influence it?
Recently, there has been a robust growth in the lung cancer diagnostic and screening market size. The market is projected to expand from $2.34 billion in 2024 to a greater value of $2.56 billion in 2025, with a steady compound annual growth rate (CAGR) of 9.6%. The strong growth witnessed in the past can be credited to factors such as advancements in digital imaging, the introduction of standardized screening protocols, public health drives to combat tobacco usage, the inception of cancer registries, and progress made in pathology analysis.

In the coming years, the lung cancer diagnostic and screening market is predicted to experience substantial growth. By 2029, the market is forecasted to reach $3.69 billion, with a compound annual growth rate (CAGR) of 9.5%. Factors contributing to this growth during the forecast period include a rise in lung cancer incidence, heightened focus on early detection, proliferation of high-risk screening initiatives, the transition to personalized medicine, as well as government support and funding. Key trends during the forecast period comprise the arrival of new screening methods, biomarker testing advancements, widespread adoption of artificial intelligence (AI), an increase in liquid biopsy use, emphasis on early stage detection, and the growth of low-dose CT screening programs.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

How are the latest trends influencing the growth of the lung cancer diagnostic and screening market?
Leading firms in the lung cancer diagnostic and screening market are working on the advancement of technologies such as lung cancer examinations to bolster early detection, enhance diagnostic precision, and aid customized treatment plans for patients in danger of developing the condition. Lung cancer tests are designed to determine the existence of lung cancer using various techniques, ranging from imaging, biomarker assessment, to cytological tests. Freenome, a biotechnology organization based in the US, for example, launched PROACT LUNG in December 2023. The introduction of the PROACT LUNG trial signifies a promising move towards transforming lung cancer screening, potentially resulting in improved early detection and superior patient results, while tackling current screening shortcomings.

What are the major segments of the lung cancer diagnostic and screening market and their role in driving growth?
The lung cancer diagnostic and screening market covered in this report is segmented -

1) By Product: Instruments, Consumables And Accessories
2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests
3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer
4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:
1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems
2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Patient Preparation Equipment, Sample Collection Kits, Laboratory Supplies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12043

Which regions are key players in the growth of the lung cancer diagnostic and screening market?
North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the lung cancer diagnostic and screening market?
Major companies operating in the lung cancer diagnostic and screening market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix,

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

What Is Covered In The Lung Cancer Diagnostic And Screening Global Market Report?

• Market Size Forecast: Examine the lung cancer diagnostic and screening market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the lung cancer diagnostic and screening market for a structured understanding.
• Key Players Overview: Analyze major players in the lung cancer diagnostic and screening market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the lung cancer diagnostic and screening market.
• Segment Contributions: Evaluate how different segments drive overall growth in the lung cancer diagnostic and screening market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the lung cancer diagnostic and screening market.
• Industry Challenges: Identify potential risks and obstacles affecting the lung cancer diagnostic and screening market.
• Competitive Landscape: Review strategic developments in the lung cancer diagnostic and screening market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.